SHS sells ProBioGen to Minapharm Pharmaceuticals for €30.4 million
SHS Beteiligungsmanagement has sold ProBioGen to Cairo-based strategic investor Minapharm Pharmaceuticals.
Minapharm acquires 95% of ProBioGen's share capital, with a total purchase price of €30.4m including earn-out payments, which are conditional upon the achievement of defined milestones.
Berlin-based ProBioGen is a German cell line development and contract manufacturing specialist and was backed by VC funds of SHS, CFH fund by LBBWGroup, IBG and tbg.
More on DACH
Dataciders sponsor Auctus mulls sale via Houlihan Lokey
German GP first acquired the local IT services group in May 2019 via Auctus V, a 2019-vintage
Bregal eyes local deal origination with new Swiss office
GP's third fund is completing its investment period, with fourth fund registered
Newly launched Utopia Capital aims to deploy EUR 10m-plus by 2028
Angel investor Christian Schroeder's new investment vehicle will support early-stage tech companies addressing humanitarian issues
Germany's DFL to collect NBOs for EUR 3bn media rights stake
Large-cap sponsors including Advent, Blackstone, Bridgepoint, CVC, EQT and KKR expected to bid today
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds